Hormone receptor status does not alter the effect of trastuzumab in breast cancer.

Abstract:

:Overexpression of human epidermal growth factor receptor 2 (HER2) predicts response to anti-HER2 therapy in breast cancer. We investigated whether hormone receptor (HR) status influences the treatment benefit of trastuzumab in patients with breast cancer. Data from 8338 patients with primary nonmetastatic breast cancer from the cancer registry of Saxony-Anhalt Germany were analyzed. A total of 5554 patients were eligible for analysis. The median follow-up of the study was 6 years. Of the 5554 patients investigated, 1128 (20.3%) showed HER2 overexpression and 656 (58.2%) of them received adjuvant trastuzumab. The 10-year overall survival (OS) in the study cohort according to HR, HER2 status, and trastuzumab treatment was as follows: 78.4% for HR-/HER2-, 85.0% for HR+/HER2-, 70.4% HR-/HER2+/TRA-, 71.4% for HR+/HER2+/TRA-, 80.9% for HR-/HER2+/TRA+, and 89.2% for HR+/HER2+/TRA+. Trastuzumab treatment improved OS in the HR- patients only in the first 3 years, whereas in the HR+ group the effect of trastuzumab was still apparent 5 years after diagnosis. Notably, the relative improvement in a patient outcome was higher for HR+ patients. Nevertheless, matching for age, histological type, tumor stage, tumor grade, and performance status between patients with HR- and HR+ tumors demonstrated that the survival effect of trastuzumab was not affected by HR status; P=0.890. Trastuzumab treatment improves patients' survival regardless of HR status and should be offered to all HER2+ patients.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Ignatov T,Eggemann H,Burger E,Costa SD,Ignatov A

doi

10.1530/ERC-16-0084

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

349-55

issue

5

eissn

1351-0088

issn

1479-6821

pii

ERC-16-0084

journal_volume

23

pub_type

杂志文章
  • CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.

    abstract::Pancreatic neuroendocrine neoplasms (PNENs) constitute a rare tumour entity, and prognosis and treatment options depend on tumour-mediating hallmarks such as angiogenesis, proliferation rate and resistance to apoptosis. The molecular pathways that determine the malignant phenotype are still insufficiently understood a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0152

    authors: Krug S,Kühnemuth B,Griesmann H,Neesse A,Mühlberg L,Boch M,Kortenhaus J,Fendrich V,Wiese D,Sipos B,Friemel J,Gress TM,Michl P

    更新日期:2014-01-01 00:00:00

  • Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

    abstract::Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-Pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0100

    authors: Krauss T,Ferrara AM,Links TP,Wellner U,Bancos I,Kvachenyuk A,Villar Gómez de Las Heras K,Yukina MY,Petrov R,Bullivant G,von Duecker L,Jadhav S,Ploeckinger U,Welin S,Schalin-Jäntti C,Gimm O,Pfeifer M,Ngeow J,Hasse-Laza

    更新日期:2018-09-01 00:00:00

  • Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.

    abstract::Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced symptomatic or progressive medullary thyroid cancer (MTC). The current study (Nbib1496313) evaluated the benefit-risk of two starting doses of vandetanib in patients with symptomatic or progressive MTC. Patients were randomized 1:1 to r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1530/ERC-18-0258

    authors: Hu MI,Elisei R,Dedecjus M,Popovtzer A,Druce M,Kapiteijn E,Pacini F,Locati L,Krajewska J,Weiss R,Gagel RF

    更新日期:2019-02-01 00:00:00

  • YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors.

    abstract::The Hippo signaling pathway has been implicated as a conserved regulator of organ size in both Drosophila and mammals. Yes-associated protein (YAP), the central component of the Hippo signaling cascade, functions as an oncogene in several malignancies. Ovarian granulosa cell tumors (GCT) are characterized by enlargeme...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0339

    authors: Fu D,Lv X,Hua G,He C,Dong J,Lele SM,Li DW,Zhai Q,Davis JS,Wang C

    更新日期:2014-03-04 00:00:00

  • Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.

    abstract::Carney triad (CT) is a rare condition with synchronous or metachronous occurrence of gastrointestinal stromal tumors (GISTs), paragangliomas (PGLs), and pulmonary chondromas in a patient. In contrast to Carney-Stratakis syndrome (CSS) and familial PGL syndromes, no germline or somatic mutations in the succinate dehydr...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0254

    authors: Haller F,Moskalev EA,Faucz FR,Barthelmeß S,Wiemann S,Bieg M,Assie G,Bertherat J,Schaefer IM,Otto C,Rattenberry E,Maher ER,Ströbel P,Werner M,Carney JA,Hartmann A,Stratakis CA,Agaimy A

    更新日期:2014-08-01 00:00:00

  • Comprehensive screening for PD-L1 expression in thyroid cancer.

    abstract::PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0421

    authors: Ahn S,Kim TH,Kim SW,Ki CS,Jang HW,Kim JS,Kim JH,Choe JH,Shin JH,Hahn SY,Oh YL,Chung JH

    更新日期:2017-02-01 00:00:00

  • A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation.

    abstract::Postmenopausal women on estrogen replacement therapy (ERT) have a reduced risk of developing colon cancer compared with postmenopausal women not on ERT, suggesting a role for estradiol (E2) in protection against this disease. To determine whether E2 protects against inflammation-associated colon cancer when administer...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-12-0308

    authors: Armstrong CM,Billimek AR,Allred KF,Sturino JM,Weeks BR,Allred CD

    更新日期:2013-06-27 00:00:00

  • Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

    abstract::In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1530/ERC-15-0490

    authors: Caplin ME,Pavel M,Ćwikła JB,Phan AT,Raderer M,Sedláčková E,Cadiot G,Wolin EM,Capdevila J,Wall L,Rindi G,Langley A,Martinez S,Gomez-Panzani E,Ruszniewski P,CLARINET Investigators.

    更新日期:2016-03-01 00:00:00

  • Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

    abstract::The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcr...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0017

    authors: Shiota M,Takeuchi A,Song Y,Yokomizo A,Kashiwagi E,Uchiumi T,Kuroiwa K,Tatsugami K,Fujimoto N,Oda Y,Naito S

    更新日期:2011-07-11 00:00:00

  • Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.

    abstract::Pituitary tumor-transforming gene 1-binding factor (PTTG1IP; PBF) is a multifunctional glycoprotein, which is overexpressed in a wide range of tumours, and significantly associated with poorer oncological outcomes, such as early tumour recurrence, distant metastasis, extramural vascular invasion and decreased disease-...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-16-0340

    authors: Imruetaicharoenchoke W,Fletcher A,Lu W,Watkins RJ,Modasia B,Poole VL,Nieto HR,Thompson RJ,Boelaert K,Read ML,Smith VE,McCabe CJ

    更新日期:2017-09-01 00:00:00

  • Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.

    abstract::Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized in man by parathyroid, pancreatic, pituitary and adrenal tumours. The MEN1 gene encodes a 610-amino acid protein (menin) which is a tumour suppressor. To investigate the in vivo role of menin, we developed a mouse model, by dele...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0082

    authors: Harding B,Lemos MC,Reed AA,Walls GV,Jeyabalan J,Bowl MR,Tateossian H,Sullivan N,Hough T,Fraser WD,Ansorge O,Cheeseman MT,Thakker RV

    更新日期:2009-12-01 00:00:00

  • Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

    abstract::Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized. In this study, using smal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0285

    authors: Karmakar S,Foster EA,Blackmore JK,Smith CL

    更新日期:2010-12-21 00:00:00

  • Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.

    abstract::Pheochromocytomas are catecholamine-producing tumors which are generally benign, but which can also present as or develop into malignancy. Molecular pathways of malignant transformation remain poorly understood. Pheochromocytomas express various trophic peptides which may influence tumoral cell behavior. Here, we inve...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-10-0109

    authors: Thouënnon E,Pierre A,Tanguy Y,Guillemot J,Manecka DL,Guérin M,Ouafik L,Muresan M,Klein M,Bertherat J,Lefebvre H,Plouin PF,Yon L,Anouar Y

    更新日期:2010-06-25 00:00:00

  • Peroxisome proliferator-activated receptor gamma and BRCA1.

    abstract::Peroxisome proliferator-activated receptor gamma agonists have been proposed as breast cancer preventives. Individuals who carry a mutated copy of BRCA1, DNA repair-associated gene, are at increased risk for development of breast cancer. Published data in the field suggest there could be interactions between peroxisom...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0449

    authors: Furth PA

    更新日期:2019-02-01 00:00:00

  • Genomic classification of benign adrenocortical lesions.

    abstract::Benign adrenal tumors cover a spectrum of lesions with distinct morphology and steroid secretion. Current classification is empirical. Beyond a few driver mutations, pathophysiology is not well understood. Here, a pangenomic characterization of benign adrenocortical tumors is proposed, aiming at unbiased classificatio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0128

    authors: Faillot S,Foulonneau T,Néou M,Espiard S,Garinet S,Vaczlavik A,Jouinot A,Rondof W,Septier A,Drougat L,Hécale-Perlemoine K,Ragazzon B,Rizk-Rabin M,Sibony M,Bonnet-Serrano F,Guibourdenche J,Libé R,Groussin L,Dousset B,

    更新日期:2021-01-01 00:00:00

  • Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.

    abstract::We studied the psychological performance and the quality of life in patients with differentiated thyroid carcinoma, either during treatment with chronic suppressive doses of levothyroxine, or during the withdrawal of levothyroxine needed to perform whole-body scanning with radioactive iodine, with those of appropriate...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0100601

    authors: Botella-Carretero JI,Galán JM,Caballero C,Sancho J,Escobar-Morreale HF

    更新日期:2003-12-01 00:00:00

  • Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

    abstract::Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize the pathways of molecular pathogenesis and to identify potential targets for therapy in MTC. Since epidermal growth factor receptor (EGFR)...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0304

    authors: Rodríguez-Antona C,Pallares J,Montero-Conde C,Inglada-Pérez L,Castelblanco E,Landa I,Leskelä S,Leandro-García LJ,López-Jiménez E,Letón R,Cascón A,Lerma E,Martin MC,Carralero MC,Mauricio D,Cigudosa JC,Matias-Guiu X,Roble

    更新日期:2010-01-29 00:00:00

  • Tetrac as an anti-angiogenic agent in cancer.

    abstract::The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate cancer progression and limit the effectiveness of anticancer therapy, though clinical data remain inconclusive. The capacity of thyroid horm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0058

    authors: Schmohl KA,Nelson PJ,Spitzweg C

    更新日期:2019-06-01 00:00:00

  • Genetically defined mouse models that mimic natural aspects of human prostate cancer development.

    abstract::This review is focused on mouse models for prostate cancer that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. It begins with an analysis of the similarities and differences in the gross and microscopic anatomy of the mouse and human prostate glands, and exte...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0110225

    authors: Roy-Burman P,Wu H,Powell WC,Hagenkord J,Cohen MB

    更新日期:2004-06-01 00:00:00

  • Androgen receptor corepressors and prostate cancer.

    abstract::The androgen receptor (AR) mediates the effects of male steroid hormones (androgens) and contributes to a wide variety of physiological and pathophysiological conditions. As such, the regulatory mechanisms governing AR activity are of high significance. Concerted effort has been placed on delineating the mechanisms th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01115

    authors: Burd CJ,Morey LM,Knudsen KE

    更新日期:2006-12-01 00:00:00

  • HES5 silencing is an early and recurrent change in prostate tumourigenesis.

    abstract::Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation prof...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0454

    authors: Massie CE,Spiteri I,Ross-Adams H,Luxton H,Kay J,Whitaker HC,Dunning MJ,Lamb AD,Ramos-Montoya A,Brewer DS,Cooper CS,Eeles R,UK Prostate ICGC Group.,Warren AY,Tavaré S,Neal DE,Lynch AG

    更新日期:2015-04-01 00:00:00

  • Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.

    abstract::Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0555

    authors: Viola D,Valerio L,Molinaro E,Agate L,Bottici V,Biagini A,Lorusso L,Cappagli V,Pieruzzi L,Giani C,Sabini E,Passannati P,Puleo L,Matrone A,Pontillo-Contillo B,Battaglia V,Mazzeo S,Vitti P,Elisei R

    更新日期:2016-04-01 00:00:00

  • Obesity and cancer: mechanistic insights from transdisciplinary studies.

    abstract::Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer. Herein, we summarize epidemiologic and preclinical evidence for an association between obesity and increased risk of breast and prostate cancer incidence and mortality. Moreover, we describe dat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0400

    authors: Allott EH,Hursting SD

    更新日期:2015-12-01 00:00:00

  • Stem cells in genetically-engineered mouse models of prostate cancer.

    abstract::The cancer stem cell model proposes that tumors have a hierarchical organization in which tumorigenic cells give rise to non-tumorigenic cells, with only a subset of stem-like cells able to propagate the tumor. In the case of prostate cancer, recent analyses of genetically engineered mouse (GEM) models have provided e...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0367

    authors: Shibata M,Shen MM

    更新日期:2015-12-01 00:00:00

  • Androgens, diabetes and prostate cancer.

    abstract::Metabolic disorders such as diabetes, obesity and the metabolic syndrome have been shown to modulate prostate cancer (PCa) risk and aggressiveness in population-based and experimental studies. While associations between these conditions are modest and complex, two consistent findings have emerged. First, there is obse...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0067

    authors: Grossmann M,Wittert G

    更新日期:2012-09-05 00:00:00

  • Apoptosis in breast cancer: relationship with other pathological parameters.

    abstract::Apoptosis is a frequent phenomenon in breast cancer and it can be detected by light microscopy in conventional histopathological sections or by special staining techniques. The number of apoptotic cells as a percentage of cells present, or the number of apoptotic cells per square millimetre of neoplastic tissue, is us...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060013

    authors: Lipponen P

    更新日期:1999-03-01 00:00:00

  • Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.

    abstract::It is well known that sex steroids play important roles in the development of invasive ductal carcinoma (IDC) of the human breast. However, biological significance of sex steroids remains largely unclear in ductal carcinoma in situ (DCIS), regarded as a precursor lesion of IDC, which is partly due to the fact that the...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0092

    authors: Shibuya R,Suzuki T,Miki Y,Yoshida K,Moriya T,Ono K,Akahira J,Ishida T,Hirakawa H,Evans DB,Sasano H

    更新日期:2008-03-01 00:00:00

  • Pituitary tumors contain a side population with tumor stem cell-associated characteristics.

    abstract::Pituitary adenomas cause significant endocrine and mass-related morbidity. Little is known about the mechanisms that underlie pituitary tumor pathogenesis. In the present study, we searched for a side population (SP) in pituitary tumors representing cells with high efflux capacity and potentially enriched for tumor st...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0546

    authors: Mertens F,Gremeaux L,Chen J,Fu Q,Willems C,Roose H,Govaere O,Roskams T,Cristina C,Becú-Villalobos D,Jorissen M,Poorten VV,Bex M,van Loon J,Vankelecom H

    更新日期:2015-08-01 00:00:00

  • Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

    abstract::The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0394

    authors: Bitting RL,Armstrong AJ

    更新日期:2013-05-20 00:00:00

  • Role of exon-16-deleted HER2 in breast carcinomas.

    abstract::A splice variant of the human gene HER2, lacking exon-16 (DeltaHER2) which encodes a small extracellular region, has been described. This altered receptor forms disulfide bond-stabilized homodimers. We report here that the DeltaHER2 splice variant represents about 9% of the HER2 mRNA obtained from most of the 46 breas...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01047

    authors: Castiglioni F,Tagliabue E,Campiglio M,Pupa SM,Balsari A,Ménard S

    更新日期:2006-03-01 00:00:00